The Sample: May 2018, Clinical Laboratory News

In a controversial new clinical guideline, the American College of Physicians (ACP) recommends less restrictive HbA1c targets for glycemic control in most patients with type 2 diabetes; between 7% and 8% rather than 6.5% or 7% as recommended by other groups (Ann Intern Med 2018; doi:10.7326/M17-0939).


ACP based this advice on evidence about the benefits and harms of lower HbA1c targets from clinical trials considered by the other groups in setting their HbA1c targets. “ACP’s analysis of the evidence behind existing guidelines found that treatment with drugs to targets of seven percent or less compared to targets of about eight percent did not reduce deaths or microvascular complications such as heart attack or stroke but did result in substantial harms,” said Jack Ende, MD, president of ACP. Read more >